UroGen Pharma Ltd. cash flow to debt ratio of -126.58% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

UroGen Pharma Ltd.'s free cash flow has decreased 67.66% from $-97.06M last year to $-162.73M, signaling decreasing performance

UroGen Pharma Ltd.'s debt to equity ratio is -1.48, signaling that the company spent its equity and risk bankruptcy.

UroGen Pharma Ltd.'s debt to equity ratio is -1.48, signaling that the company spent its equity and risk bankruptcy.

UroGen Pharma Ltd. has negative EBITDA, making leverage ratio unreliable

UroGen Pharma Ltd.'s interest coverage ratio is -1.93, which means that the company struggles to meet interest obligations, signaling financial risk.

UroGen Pharma Ltd.'s profit margin has increased (-63.14%) in the last year from -140.35% to -51.73%, signaling increasing performance

UroGen Pharma Ltd.'s short-term assets of $186.02M exceed its short-term liabilities of $46.42M

UroGen Pharma Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

UroGen Pharma Ltd.'s return on equity of 81.78%, is higher than 15.00%, indicating good performance

UroGen Pharma Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

UroGen Pharma Ltd. had positive net income in only 0 out of 5 years, indicating unstable earnings

UroGen Pharma Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

UroGen Pharma Ltd. has negative free cash flow, indicating cash burn

UroGen Pharma Ltd.'s yearly earnings has decreased 20.98% since last year from $-126.87M to $-153.49M, signaling decreasing performance

UroGen Pharma Ltd.'s yearly revenue has increased 21.45% since last year from $90.40M to $109.79M, signaling increasing performance

ROIC -34.41% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

UroGen Pharma Ltd.'s 3-year revenue CAGR of 19.49% is positive, indicating growing revenue over the past 3 years

UroGen Pharma Ltd. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

UroGen Pharma Ltd. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

UroGen Pharma Ltd. has insufficient data to evaluate this check.

UroGen Pharma Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

UroGen Pharma Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

UroGen Pharma Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

UroGen Pharma Ltd. is overvalued relative to its fair value price of -50.23 based on Earnings Fair Value model

UroGen Pharma Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

UroGen Pharma Ltd. has negative shareholder equity; price-to-book is not meaningful and the check fails

UroGen Pharma Ltd. has a price-to-sales ratio of 12.36x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue